114 related articles for article (PubMed ID: 29570101)
1. Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy.
Mitani A; Jo T; Yasunaga H; Sakamoto Y; Hasegawa W; Urushiyama H; Yamauchi Y; Matsui H; Fushimi K; Nagase T
Anticancer Drugs; 2018 Jul; 29(6):560-564. PubMed ID: 29570101
[TBL] [Abstract][Full Text] [Related]
2. The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
Tully CM; Apolo AB; Zabor EC; Regazzi AM; Ostrovnaya I; Furberg HF; Rosenberg JE; Bajorin DF
Cancer; 2016 Mar; 122(5):712-21. PubMed ID: 26618338
[TBL] [Abstract][Full Text] [Related]
3. Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung.
Isaka T; Nakayama H; Yokose T; Ito H; Katayama K; Yamada K; Masuda M
Ann Thorac Cardiovasc Surg; 2017 Feb; 23(1):19-25. PubMed ID: 28025447
[TBL] [Abstract][Full Text] [Related]
4. High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
Fehr M; Hawle H; Hayoz S; Thuss-Patience P; Schacher S; Riera Knorrenschild J; Dürr D; Knoefel WT; Rumpold H; Bitzer M; Zweifel M; Samaras P; Mey U; Küng M; Winterhalder R; Eisterer W; Hess V; Gérard MA; Templeton A; Stahl M; Ruhstaller T; ; ; ;
BMC Cancer; 2020 Feb; 20(1):166. PubMed ID: 32111181
[TBL] [Abstract][Full Text] [Related]
5. Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.
Bamias A; Tzannis K; Dimitriadis I; Tsironis G; Papatheorodidi AM; Tsiara A; Fragkoulis C; Xirokosta A; Barbarousi D; Papadopoulos G; Zakopoulou R; Varkarakis I; Mitsogiannis I; Adamakis I; Alamanis C; Stravodimos K; Papatsoris AG; Dellis AE; Drivalos A; Ntoumas K; Matsouka H; Halvatsiotis P; Raptis A; Gerotziafas GT; Dimopoulos MA
Clin Genitourin Cancer; 2020 Aug; 18(4):e457-e472. PubMed ID: 32007440
[TBL] [Abstract][Full Text] [Related]
6. Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Mellema WW; van der Hoek D; Postmus PE; Smit EF
Lung Cancer; 2014 Oct; 86(1):73-7. PubMed ID: 25129368
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
[TBL] [Abstract][Full Text] [Related]
8. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
Klastersky J; Sculier JP; Lacroix H; Dabouis G; Bureau G; Libert P; Richez M; Ravez P; Vandermoten G; Thiriaux J
J Clin Oncol; 1990 Sep; 8(9):1556-62. PubMed ID: 2167953
[TBL] [Abstract][Full Text] [Related]
9. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
Seng S; Liu Z; Chiu SK; Proverbs-Singh T; Sonpavde G; Choueiri TK; Tsao CK; Yu M; Hahn NM; Oh WK; Galsky MD
J Clin Oncol; 2012 Dec; 30(35):4416-26. PubMed ID: 23150697
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.
De Andrés L; Brunet J; López-Pousa A; Burgués J; Vega M; Tabernero JM; Mesía R; López JJ
J Clin Oncol; 1995 Jun; 13(6):1493-500. PubMed ID: 7751897
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness analysis comparing carboplatin and weekly paclitaxel with cisplatin and docetaxel in the treatment of advanced non-small cell lung carcinoma].
Inage S; Ise Y; Obayashi M; Katayama S; Gemma A
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2093-100. PubMed ID: 21084806
[TBL] [Abstract][Full Text] [Related]
12. [Phase I clinical study of combined cisplatin and carboplatin therapy in lung cancer].
Hayasaka S; Yoshinaga T; Kinuwaki E; Kiyama T; Fujino N
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2011-6. PubMed ID: 1417008
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
Piccart MJ; Nogaret JM; Marcelis L; Longrée H; Ries F; Kains JP; Gobert P; Domange AM; Sculier JP; Gompel C
J Natl Cancer Inst; 1990 Apr; 82(8):703-7. PubMed ID: 2181152
[TBL] [Abstract][Full Text] [Related]
14. [Probability of the combination use of cisplatin and carboplatin].
Kobayashi K; Hino M; Hayashihara K; Niitani H
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2684-92. PubMed ID: 2277219
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of combined nedaplatin and docetaxel therapy for human head and neck cancer in vivo.
Yamada H; Maki H; Takeda Y; Orita S
Anticancer Res; 2006; 26(2A):989-94. PubMed ID: 16619497
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer.
Lee YG; Lee E; Kim I; Lee KW; Kim TM; Lee SH; Kim DW; Heo DS
Cancer Res Treat; 2015 Oct; 47(4):670-5. PubMed ID: 25672586
[TBL] [Abstract][Full Text] [Related]
17. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
Lorusso D; Petrelli F; Coinu A; Raspagliesi F; Barni S
Gynecol Oncol; 2014 Apr; 133(1):117-23. PubMed ID: 24486604
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Starling N; Rao S; Cunningham D; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR
J Clin Oncol; 2009 Aug; 27(23):3786-93. PubMed ID: 19398575
[TBL] [Abstract][Full Text] [Related]
19. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy - a cohort study.
Zahir MN; Shaikh Q; Shabbir-Moosajee M; Jabbar AA
BMC Cancer; 2017 Jan; 17(1):57. PubMed ID: 28093087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
